NasdaqGS:INDVPharmaceuticals
Does Indivior’s Upsized Convertible Notes and Buybacks Shift the Bull Case For Indivior (INDV)?
Indivior Pharmaceuticals recently completed an upsized private offering of US$450 million in 0.625% convertible senior unsecured notes due March 15, 2031, with proceeds earmarked for repaying existing borrowings, repurchasing approximately 2.4 million shares, and general corporate purposes.
Alongside this financing move, the company reported better-than-expected 2025 earnings and saw directors purchase additional shares, underscoring management’s confidence and balance sheet reshaping...